Using a PE-conjugated anti Tie-2 antibody, the expression level of the Tie-2 receptor in a panel of prostate cancer cell lines with different metastatic potential (LAPC4, 22Rv1, DU145, LNCaP, C42B, MDA-PCa-2b and PC-3) was determined by flow cytometry. Here, TEK is linked to prostate carcinoma.